PARP Inhibitor Plus Immunotherapy Shows Limited Benefit in BRCA-Mutant Ovarian Cancer

Fifty women with recurrent ovarian cancer and germline BRCA mutations enrolled in a clinical trial testing whether combining two drugs—olaparib, a PARP inhibitor, and tremelimumab, an immune checkpoint antibody—could improve their outcomes. The logic was sound: laboratory studies had shown the combination worked synergistically in BRCA-deficient cancer models, achieving long-term survival. But the real world rarely mirrors the petri dish.

The trial, conducted across multiple sites and registered as NCT02571725, was structured as a phase I/II study. The phase I portion, which enrolled just three women, identified no new safety concerns when the drugs were given together. That cleared the path for phase II, where the real test would come. Ultimately, 49 women completed the safety evaluation—a heavily pre-treated population, meaning most had already exhausted other options.

What emerged was a picture of modest benefit shadowed by substantial harm. Among the 49 women in the combined safety cohort, 57 percent experienced grade 3 or 4 non-hematologic toxicity—the kind of serious side effects that land patients in the hospital or force them to stop treatment. Indeed, more than one-third of the women discontinued tremelimumab because the adverse effects became intolerable. The body's immune system, once unleashed by the checkpoint inhibitor, had turned against them in ways the researchers had not anticipated.

The primary measure of success—overall response rate—came in at 32.7 percent, with a 95 percent confidence interval of 19.5 to 45.8 percent. The trial had a prespecified efficacy endpoint it needed to meet, and this result fell short. Disease control rate, a broader measure that includes stable disease alongside actual tumor shrinkage, reached 47.7 percent. Median progression-free survival was 3.0 months. Median overall survival stretched to 24.3 months, a figure that sounds longer but must be understood in context: these were women whose cancers had already recurred, women for whom options were running out.

Yet the data contained a glimmer. Six women in this heavily pre-treated cohort achieved progression-free survival beyond 12 months—a meaningful duration in recurrent ovarian cancer. That observation, modest as it was, suggested that the combination was not useless; rather, it worked for some patients and not others. The question became: which ones?

In exploratory post-hoc analyses, researchers examined biomarkers—molecular signatures that might predict who would benefit. Two emerged: low expression of VSTM5 and low expression of IFIT1B were associated with treatment benefit and improved progression-free survival, with a p-value less than 0.001. These were not prespecified endpoints; they were discovered after the fact, which means they require validation in future studies before they can guide clinical practice. But they pointed toward a path forward: the combination might work well if doctors could first identify which patients carried these molecular signatures.

The trial's failure to meet its primary endpoint was real and significant. Immunotherapy has struggled in ovarian cancer—response rates to checkpoint blockade alone remain low—and the hope had been that adding a PARP inhibitor would unlock better results. It did not, at least not broadly. But the emergence of potential biomarkers suggested that the future of this combination, if it has one, lies not in treating all BRCA-mutant patients alike but in selecting those most likely to respond. For a disease as relentless as recurrent ovarian cancer, even a 32.7 percent response rate in the right subset of patients might matter.